Article Text

PDF

COPD and drugs: new and old concepts
P254 NVA237 once daily improves exercise endurance in patients with COPD from the first dose: the GLOW3 trial
  1. D Singh1,
  2. K Beeh2,
  3. A Drollmann3,
  4. L Di Scala3,
  5. R Smith4
  1. 1University of Manchester, Medicines Evaluation Unit, Manchester, UK
  2. 2insaf Respiratory Research Institute, Wiesbaden, Germany
  3. 3Novartis Pharma AG, Basel, Switzerland
  4. 4Novartis Horsham Research Centre, West Sussex, UK

Abstract

Introduction The fundamental characteristics of COPD are exertional dyspnoea and exercise limitation, which are associated with dynamic hyperinflation. We assessed the effects of NVA237 (glycopyrronium bromide), a once-daily long-acting muscarinic antagonist (LAMA), on exercise endurance in patients with moderate-to-severe COPD.

Methods Patients with COPD were randomised to a cross-over design of NVA237 50 μg or placebo once daily for 3 weeks, with a 14-day washout. The primary endpoint was endurance time during a submaximal constant-load cycle ergometry test (SMETT) on Day 21 of treatment. Endurance time after first dose, dynamic hyperinflation (inspiratory capacity [IC] at isotime during exercise), and morning trough FEV1 and plethysmographic lung volumes were also measured.

Results 108 patients were randomised; mean age was 60.5 years, mean post-bronchodilator FEV1 was 57.1% predicted. 88.0% completed the study. Endurance time on Day 21 significantly increased by 21% with NVA237 vs placebo; the effect was significant from Day 1, with an increase of 10%. Both dynamic IC at exercise isotime and trough FEV1 showed significant and clinically relevant improvements from Day 1 that were maintained for the study duration (Abstract P254 table 1). This was accompanied by inverse decreases in residual volume and functional residual capacity (Abstract P254 table 1). Overall, the safety profile of NVA237 was similar to that of placebo.

Abstract P254 Table 1

NVA237 treatment effects vs placebo

Conclusion Once-daily NVA237 provided immediate and significant improvement in exercise endurance from Day 1. This was accompanied by sustained and significant improvements in IC at isotime, meaningful improvements in trough FEV1, and sustained reductions of lung hyperinflation. There was an improvement in endurance time during the study period, suggesting that mechanisms beyond improved lung function play a part in superior exercise tolerance.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.